AbbVie Inc. (ABBV) stock price, chart and research
AbbVie Inc. (ABBV) last traded at $293.30 at the close on November 9, 2026, up $1.99 (0.68%) on the day. In after-hours trading it was $293.30.
- Day range: $289.62 to $294.57
- 52-week range: $190.75 to $302.93
- Market cap: $518.44 billion
- P/E (trailing 12 months): 50.40
- Forward P/E: 18.12
- EPS (trailing 12 months): $5.82
- Dividend yield: 2.38%
- Volume: 5,822,420 shares
About AbbVie Inc.
Sector: Healthcare; industry: Drug Manufacturers - General; headquarters: United States; CEO: Mr. Robert A. Michael CPA; 57,000 employees; listed since 2013-01-02.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers…
Financials
Revenue over the last 12 months was $66.01 billion, net income $10.30 billion, a profit margin of 15.7%. Revenue grew 10.7% from a year earlier.
Institutional owners of ABBV (13F)
Tracked managers holding ABBV in 13F filings for the quarter ending 2026-09-30:
- Dimensional Fund Advisors LP: $1.74 billion, 0.32% of its portfolio (reduced)
- Wolverine Asset Management LLC: $356,000.00, 0.01% of its portfolio (new)
ETFs that hold ABBV
- SPY: SPDR S&P 500 ETF
- XLV: Health Care Select Sector SPDR
- VOO: Vanguard S&P 500 ETF
- IVV: iShares Core S&P 500 ETF
- VTI: Vanguard Total Stock Market
- ITOT: iShares Core S&P Total US
Research ABBV with LunaTerminal
- Interactive chart from one day to ten years, with volume, technicals and comparisons.
- Valuation, analyst ratings, dividends, earnings history and recent news.
- Ask LunaTerminal about ABBV: AI answers that cite dated data; no account needed for 5 prompts
- 13F filings: which managers own what
- How advisors use LunaTerminal for market research
Data: Yahoo Finance via Fear & Greed (feargreedflow.com); 13F holdings from SEC filings. Market data can be delayed; check dates before relying on a figure. Answers are research, not financial advice.